{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:22:07Z","timestamp":1792027327021,"version":"4.4.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hereditary hemorrhagic telangiectasia (HHT), the second most common inherited bleeding disorder, is associated with the development of malformed blood vessels. Abnormal blood vessels may be small and cutaneous or mucosal (telangiectasia), with frequent complications of bleeding, or large and visceral (arteriovenous malformations [AVMs]), with additional risks that can lead to significant morbidity and even mortality. HHT can present in many different ways and can be difficult to recognize, particularly in younger patients in the absence of a known family history of disease or epistaxis, its most common manifestation. HHT is commonly diagnosed using the established Cura\u00e7ao clinical criteria, which include (1) family history, (2) recurrent epistaxis, (3) telangiectasia, and (4) visceral AVMs. Fulfillment of 3 or more criteria provides a definite diagnosis of HHT, whereas 2 criteria constitute a possible diagnosis of HHT. However, these criteria are insufficient in children to rule out disease due to the age-dependent development of some of these criteria. Genetic testing, when positive, can provide definitive diagnosis of HHT in all age groups. Clinical course is often complicated by significant epistaxis and\/or gastrointestinal bleeding, leading to anemia in half of adult patients with HHT. The management paradigm has recently shifted from surgical approaches to medical treatments aimed at control of chronic bleeding, such as antifibrinolytic and antiangiogenic agents, combined with aggressive iron replacement with intravenous iron. Guidelines for management of HHT, including screening and treatment, were determined by expert consensus and originally published in 2009 with updates and new guidelines in 2020.<\/jats:p>","DOI":"10.1182\/hematology.2021000281","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T07:16:01Z","timestamp":1639120561000},"page":"469-477","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management"],"prefix":"10.1182","volume":"2021","author":[{"given":"Adrienne M.","family":"Hammill","sequence":"first","affiliation":[{"name":"Cancer and Blood Diseases Institute, Division of Hematology, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Wusik","sequence":"additional","affiliation":[{"name":"Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj S.","family":"Kasthuri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"12","key":"2021121012080437600_hem2021000281C1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"2021121012080437600_hem2021000281C2","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.ejim.2012.12.013","article-title":"Hereditary hemorrhagic telangiectasia, liver vascular malformations and cardiac consequences","volume":"24","author":"Ginon","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"4","key":"2021121012080437600_hem2021000281C3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2217\/bmm-2017-0229","article-title":"Vitamin D levels are associated with epistaxis severity and bleeding duration in hereditary hemorrhagic telangiectasia","volume":"12","author":"Weber","year":"2018","journal-title":"Biomark Med"},{"key":"2021121012080437600_hem2021000281C4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jpeds.2018.12.069","article-title":"Growth of pulmonary arteriovenous malformations in pediatric patients with hereditary hemorrhagic telangiectasia","volume":"208","author":"Ratjen","year":"2019","journal-title":"J Pediatr"},{"key":"2021121012080437600_hem2021000281C5","first-page":"531","article-title":"Incidence of epistaxis and telangiectases in the general population","volume":"18","author":"McDonald","year":"2017","journal-title":"Angiogenesis"},{"issue":"1","key":"2021121012080437600_hem2021000281C6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2796.1999.00398.x","article-title":"Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients","volume":"245","author":"Kjeldsen","year":"1999","journal-title":"J Intern Med"},{"issue":"7","key":"2021121012080437600_hem2021000281C7","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/ajmg.a.38695","article-title":"Tissue-specific mosaicism in hereditary hemorrhagic telangiectasia: implications for genetic testing in families","volume":"176","author":"McDonald","year":"2018","journal-title":"Am J Med Genet A"},{"issue":"1","key":"2021121012080437600_hem2021000281C8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mgg3.361","article-title":"ENG mutational mosaicism in a family with hereditary hemorrhagic telangiectasia","volume":"6","author":"T\u00f8rring","year":"2018","journal-title":"Mol Genet Genomic Med"},{"issue":"5","key":"2021121012080437600_hem2021000281C9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/jmg.2010.088286","article-title":"Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patients","volume":"48","author":"Best","year":"2011","journal-title":"J Med Genet"},{"issue":"5","key":"2021121012080437600_hem2021000281C10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmg.2010.088112","article-title":"Identification of clinically relevant mosaicism in type I hereditary haemorrhagic telangiectasia","volume":"48","author":"Lee","year":"2011","journal-title":"J Med Genet"},{"issue":"2","key":"2021121012080437600_hem2021000281C11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2353\/jmoldx.2007.060117","article-title":"Clinical and analytical sensitivities in hereditary hemorrhagic telangiectasia testing and a report of de novo mutations","volume":"9","author":"Gedge","year":"2007","journal-title":"J Mol Diagn"},{"issue":"1","key":"2021121012080437600_hem2021000281C12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am J Med Genet"},{"key":"2021121012080437600_hem2021000281C13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1750-1172-7-33","article-title":"A long diagnostic delay in patients with hereditary haemorrhagic telangiectasia: a questionnaire-based retrospective study","volume":"7","author":"Pierucci","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"2021121012080437600_hem2021000281C14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jpeds.2018.01.079","article-title":"Applicability of the Cura\u00e7ao criteria for the diagnosis of hereditary hemorrhagic telangiectasia in the pediatric population","volume":"197","author":"Pahl","year":"2018","journal-title":"J Pediatr"},{"issue":"2","key":"2021121012080437600_hem2021000281C15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2009.069013","article-title":"International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia","volume":"48","author":"Faughnan","year":"2011","journal-title":"J Med Genet"},{"issue":"7","key":"2021121012080437600_hem2021000281C16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41436-020-0775-8","article-title":"Cura\u00e7ao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2)","volume":"22","author":"McDonald","year":"2020","journal-title":"Genet Med"},{"issue":"10","key":"2021121012080437600_hem2021000281C17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jmg.2006.041517","article-title":"SMAD4 mutations found in unselected HHT patients","volume":"43","author":"Gallione","year":"2006","journal-title":"J Med Genet"},{"key":"2021121012080437600_hem2021000281C18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/ajmg.a.33206","article-title":"Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome","volume":"152A(2)","author":"Gallione","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"8","key":"2021121012080437600_hem2021000281C19","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/ajmg.a.37093","article-title":"Prevalence of thoracic aortopathy in patients with juvenile polyposis syndrome\u2013hereditary hemorrhagic telangiectasia due to SMAD4","volume":"167","author":"Heald","year":"2015","journal-title":"Am J Med Genet A"},{"key":"2021121012080437600_hem2021000281C20","doi-asserted-by":"crossref","first-page":"15040","DOI":"10.1038\/hgv.2015.40","article-title":"Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia","volume":"2","author":"Hernandez","year":"2015","journal-title":"Hum Genome Var"},{"issue":"9","key":"2021121012080437600_hem2021000281C21","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41436-019-0443-z","article-title":"Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)?","volume":"21","author":"Wooderchak-Donahue","year":"2019","journal-title":"Genet Med"},{"issue":"4","key":"2021121012080437600_hem2021000281C22","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"issue":"9","key":"2021121012080437600_hem2021000281C23","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease","volume":"12","author":"Gaillard","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2021121012080437600_hem2021000281C24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid\u2014a double-blind placebo-controlled cross-over phase IIIB study","volume":"134","author":"Geisthoff","year":"2014","journal-title":"Thromb Res"},{"issue":"1","key":"2021121012080437600_hem2021000281C25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/gim.2013.62","article-title":"Endoscopic evaluation of gastrointestinal tract in patients with hereditary hemorrhagic telangiectasia and correlation with their genotypes","volume":"16","author":"Canzonieri","year":"2014","journal-title":"Genet Med"},{"issue":"10","key":"2021121012080437600_hem2021000281C26","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1002\/ajh.24832","article-title":"Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia","volume":"92","author":"Kasthuri","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2021121012080437600_hem2021000281C27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13023-017-0632-2","article-title":"Central nervous system manganese induced lesions and clinical consequences in patients with hereditary hemorrhagic telangiectasia","volume":"12","author":"Serra","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2021121012080437600_hem2021000281C28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/thoraxjnl-2011-201076","article-title":"Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli\/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia","volume":"67","author":"Livesey","year":"2012","journal-title":"Thorax"},{"issue":"2","key":"2021121012080437600_hem2021000281C29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2021121012080437600_hem2021000281C30","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2021121012080437600_hem2021000281C31","first-page":"624","article-title":"Pomalidomide in HHT: results of a pilot study","volume":"22","author":"McCrae","year":"2019","journal-title":"Angiogenesis"},{"issue":"1","key":"2021121012080437600_hem2021000281C32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"Faughnan","year":"2019","journal-title":"Angiogenesis"},{"issue":"4","key":"2021121012080437600_hem2021000281C33","first-page":"530","article-title":"Oral doxycycline for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia","volume":"18","author":"Meek","year":"2015","journal-title":"Angiogenesis"},{"key":"2021121012080437600_hem2021000281C34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13023-016-0427-x","article-title":"Life expectancy of parents with hereditary haemorrhagic telangiectasia","volume":"11","author":"de Gussem","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2021121012080437600_hem2021000281C35","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.mayocp.2016.07.005","article-title":"Effect of center volume on outcomes in hospitalized patients with hereditary hemorrhagic telangiectasia","volume":"91","author":"Iyer","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2021121012080437600_hem2021000281C36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13023-019-1286-z","article-title":"Hereditary haemorrhagic telangiectasia and pregnancy: a review of the literature","volume":"15","author":"Dupuis","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2021121012080437600_hem2021000281C37","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/AOG.0000000000000120","article-title":"Outcomes of pregnancy in women with hereditary hemorrhagic telangiectasia","volume":"123","author":"de Gussem","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"9","key":"2021121012080437600_hem2021000281C38","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/j.1471-0528.2008.01786.x","article-title":"Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services","volume":"115","author":"Shovlin","year":"2008","journal-title":"BJOG"},{"issue":"7","key":"2021121012080437600_hem2021000281C39","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.2020008739","article-title":"Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care","volume":"137","author":"Al-Samkari","year":"2021","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/469\/1852038\/469hammill.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/469\/1852038\/469hammill.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T17:00:26Z","timestamp":1673974826000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/469\/482972\/Hereditary-hemorrhagic-telangiectasia-HHT-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000281","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}